{"success":true,"data":{"pressRelease":{"id":"30764","rtpr_id":"nWkr5xNwXQ","ticker":"CAMX","exchange":"Nasdaq Stockholm","all_tickers":["CAMX"],"title":"Camurus' Interim Report January-March 2026","author":"Cision","published_at":"2026-05-12T05:00:16.484Z","article_body":"Camurus AB\n\"Q1 performance on track for full-year guidance\"\n\nSummary first quarter 2026\n\nJanuary - March\n* Total revenues decreased 5% (increased 3% at CER(1)) to SEK 533 (558)\nmillion\n* Product sales decreased 12% (6% at CER(1)) to SEK 426 (485) million\n* Royalties increased 44% (59% at CER(1)) to SEK 106 (74) million\n* Operating result decreased 30% (15% at CER(1)) to SEK 168 (239) million\n* Profit before tax decreased 28% (14% at CER(1)) to SEK 184 (254) million\n* The cash position at the end of the quarter was SEK 3.9 (2.9) billion\n* FDA accepted the Oclaiz™ NDA for review with PDUFA action date 10 June,\n2026\n* Financial outlook 2026 reiterated \n1. At constant exchange rate\nFredrik Tiberg, President and CEO:\n\"Camurus' first quarter 2026 results were in line with our expectations and\nfull-year guidance. Following changes to the distribution model in the UK in\nQ4 2025, sales revenues recovered, while our R&D pipeline continued to\nadvance. We are expecting the approval decision for Oclaiz™ in the US on 10\nJune and thereafter look forward to completing the randomized part of the\nSORENTO study in GEP-NET and sharing the primary Phase 3 results.\"\n\nWebcast\nFinancial analysts, investors and media are invited to attend a webcast and\npresentation of the results at 2.00 pm CET.\n\nAccess the webcast using this link:\nhttps://camurus.events.inderes.com/q1-report-2026\n\nTo participate in the presentation and ask questions, please register using\nthe link below. After registering, please use the provided phone number and\nconference ID to dial in:\nhttps://events.inderes.com/camurus/q1-report-2026/dial-in\n\nFor more information:\nFredrik Tiberg, President and CEO\nfredrik.tiberg@camurus.com\n\nFredrik Joabsson, Chief Business Development Officer\nTel. +46 (0)70 776 17 37\nir@camurus.com\n\nAbout Camurus\nCamurus is an international, science-led biopharmaceutical company committed\nto developing and commercializing innovative, long-acting medicines for\nimproving the lives of patients with severe and chronic diseases. New drug\nproducts with best-in-class potential are conceived based on the company's\nproprietary FluidCrystal(®) technology and its extensive R&D expertise. The\nR&D pipeline includes products for the treatment of dependence, pain, cancer,\nand endocrine diseases. Camurus has operations across Europe, the US, and\nAustralia, with headquarters in Lund, Sweden. The company's shares are listed\non Nasdaq Stockholm under the ticker CAMX. For more information, visit\nwww.camurus.com and LinkedIn (https://www.linkedin.com/company/Camurus).\n\nThis information is information that Camurus AB is obliged to make public\npursuant to the EU Market Abuse Regulation. The information was submitted for\npublication, through the agency of the chief executive officer, at 07.00 am\nCET on 12 May, 2026.\n\nhttps://news.cision.com/camurus-ab/r/camurus--interim-report-january-march-2026%2Cc4347347\n\nCamurus Interim Report First Quarter 2026\n(https://mb.cision.com/Main/13456/4347347/4088592.pdf)\n\n\n\n(c) Copyright Waymaker BIT News - Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr5xNwXQ","title":"Camurus' Interim Report January-March 2026","author":"Cision","ticker":"CAMX","created":"2026-05-12T05:00:16.484Z","tickers":["CAMX"],"exchange":"Nasdaq Stockholm","article_body":"Camurus AB\n\"Q1 performance on track for full-year guidance\"\n\nSummary first quarter 2026\n\nJanuary - March\n* Total revenues decreased 5% (increased 3% at CER(1)) to SEK 533 (558)\nmillion\n* Product sales decreased 12% (6% at CER(1)) to SEK 426 (485) million\n* Royalties increased 44% (59% at CER(1)) to SEK 106 (74) million\n* Operating result decreased 30% (15% at CER(1)) to SEK 168 (239) million\n* Profit before tax decreased 28% (14% at CER(1)) to SEK 184 (254) million\n* The cash position at the end of the quarter was SEK 3.9 (2.9) billion\n* FDA accepted the Oclaiz™ NDA for review with PDUFA action date 10 June,\n2026\n* Financial outlook 2026 reiterated \n1. At constant exchange rate\nFredrik Tiberg, President and CEO:\n\"Camurus' first quarter 2026 results were in line with our expectations and\nfull-year guidance. Following changes to the distribution model in the UK in\nQ4 2025, sales revenues recovered, while our R&D pipeline continued to\nadvance. We are expecting the approval decision for Oclaiz™ in the US on 10\nJune and thereafter look forward to completing the randomized part of the\nSORENTO study in GEP-NET and sharing the primary Phase 3 results.\"\n\nWebcast\nFinancial analysts, investors and media are invited to attend a webcast and\npresentation of the results at 2.00 pm CET.\n\nAccess the webcast using this link:\nhttps://camurus.events.inderes.com/q1-report-2026\n\nTo participate in the presentation and ask questions, please register using\nthe link below. After registering, please use the provided phone number and\nconference ID to dial in:\nhttps://events.inderes.com/camurus/q1-report-2026/dial-in\n\nFor more information:\nFredrik Tiberg, President and CEO\nfredrik.tiberg@camurus.com\n\nFredrik Joabsson, Chief Business Development Officer\nTel. +46 (0)70 776 17 37\nir@camurus.com\n\nAbout Camurus\nCamurus is an international, science-led biopharmaceutical company committed\nto developing and commercializing innovative, long-acting medicines for\nimproving the lives of patients with severe and chronic diseases. New drug\nproducts with best-in-class potential are conceived based on the company's\nproprietary FluidCrystal(®) technology and its extensive R&D expertise. The\nR&D pipeline includes products for the treatment of dependence, pain, cancer,\nand endocrine diseases. Camurus has operations across Europe, the US, and\nAustralia, with headquarters in Lund, Sweden. The company's shares are listed\non Nasdaq Stockholm under the ticker CAMX. For more information, visit\nwww.camurus.com and LinkedIn (https://www.linkedin.com/company/Camurus).\n\nThis information is information that Camurus AB is obliged to make public\npursuant to the EU Market Abuse Regulation. The information was submitted for\npublication, through the agency of the chief executive officer, at 07.00 am\nCET on 12 May, 2026.\n\nhttps://news.cision.com/camurus-ab/r/camurus--interim-report-january-march-2026%2Cc4347347\n\nCamurus Interim Report First Quarter 2026\n(https://mb.cision.com/Main/13456/4347347/4088592.pdf)\n\n\n\n(c) Copyright Waymaker BIT News - Cision 2026"},"type":"article","timestamp":"2026-05-12T05:00:16.541051652Z","server_sent_at_ms":1778562016541},"received_at":"2026-05-12T05:00:16.596Z","source_url":"https://news.cision.com/camurus-ab/r/camurus--interim-report-january-march-2026%2Cc4347347"},"analysis":null,"durationMs":null,"modelName":null}}